New granule drug could ease tumors in toddlers with NF1

NCT ID NCT05309668

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a granule (sprinkle) form of the drug selumetinib in children aged 1 to under 7 years who have neurofibromatosis type 1 (NF1) with painful, inoperable tumors. The goal is to find the right dose, check safety, and see if it shrinks tumors. About 36 children will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibromatosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROFIBROMATOSIS TYPE 1

Contacts and locations

Show contact details

Locations

Research Site

Akron, Ohio, 44308, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Richmond, Virginia, 23219, United States
Research Site

Hamburg, 20246, Germany
Research Site

München, 80337, Germany
Research Site

Tübingen, 72076, Germany
Research Site

Milan, 20133, Italy
Research Site

Rome, 00165, Italy
Research Site

Nagoya, 466-8560, Japan
Research Site

Setagaya City, 157-8535, Japan
Research Site

Rotterdam, 3015 GD, Netherlands
Research Site

Moscow, 119620, Russia
Research Site

Moscow, 125412, Russia
Research Site

Barcelona, 08950, Spain
Research Site

Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.